Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

Fig. 2

Changes in DAS28-CRP (mean ± SD) over time in patients whose data were used in the analysis of effectiveness (n = 135) (a). Proportion of patients with LDA during the study period (b). Comparison of proportion of patients with LDA at the end of the HOPEFUL-3 study period (week 208) according to the initial therapy in the ADA continuation group (c) and in the ADA discontinuation group (d). ADA Adalimumab, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, LDA Low disease activity, MTX Methotrexate

Back to article page